



Tissue factor pathway inhibitor – cofactor-dependent regulation of the initiation of coagulation

Josefin Ahnström, Anastasis Petri and James T.B. Crawley

Purpose of review

In humans, tissue factor pathway inhibitor (TFPI) exists in two alternatively spliced isoforms, TFPI α and TFPI β . TFPI α consists of three Kunitz domains (K1, K2 and K3) and a highly basic C-terminal tail. K1 inhibits the tissue factor-activated factor VII complex, K2 specifically inhibits activated factor X, K3 is essential for interaction with its cofactor, protein S, and the basic C-terminus binds factor V-short (FV-short) with high affinity. TFPI β consists of K1 and K2 that is glycosylphosphatidylinositol anchored directly to cell surfaces. This review explores the structure/function of TFPI and its cofactors (protein S and FV-short), and the relative contributions that different TFPI isoforms may play in haemostatic control.

Recent findings

Recent data have underscored the importance of TFPI α function and its reliance on its cofactors, protein S and FV-short, in influencing haemostatic control as well as bleeding and thrombotic risk

Summary

TFPI α is likely the most important pool of TFPI in modifying the risk of thrombosis and bleeding. TFPI α forms a trimolecular complex with FV-short and protein S in plasma. FV-short expression levels control the circulating levels of TFPI α , whereas protein S exerts essential cofactor mediated augmentation of its anticoagulant function.

Keywords

anticoagulant, factor V short, haemostasis, protein S, tissue factor pathway inhibitor

INTRODUCTION

Haemostasis corresponds to the cellular and biochemical processes that limit bleeding following blood vessel damage. To be effective, the haemostatic response at the site of vessel injury must be rapid but also highly controlled to specifically localize clot formation – both spatially and temporally. Haemostasis is, therefore, finely balanced by highly orchestrated procoagulant and anticoagulant mechanisms. Tissue factor (TF) initiated coagulation is the major mechanism that initiates thrombin generation after vascular injury. TF is a transmembrane glycoprotein expressed on the surface of various cells, particularly those surrounding blood vessels. When vascular integrity is compromised, TF is exposed to circulating plasma activated factor VII (FVIIa). TF binding allosterically activates FVIIa enabling it to proteolytically activate factor X (FX) to factor Xa (FXa) and factor IX to activated factor IX – together these steps correspond to the initiation phase of coagulation. FXa inefficiently converts small amounts of prothrombin to thrombin.

Thrombin activates platelets and other coagulation prococfactors, including factor VIII (FVIII) and factor V (FV). FVIIIa forms the tenase complex with activated factor IX to amplify FXa generation. After activation, FXa is released and incorporated into the prothrombinase complex together with FVa, resulting in a strong enhancement of thrombin generation and the start of the propagation phase of

Centre for Haematology, Department of Immunology and Inflammation, Hammersmith Hospital Campus, Imperial College London, London, UK

Correspondence to Prof. James T.B. Crawley, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital Campus, 5th Floor Commonwealth Building, Du Cane Road, London, W12 0NN, UK. Tel: +44 20 3313 2297; e-mail: j.crawley@imperial.ac.uk

Curr Opin Hematol 2024, 31:315–320

DOI:10.1097/MOH.0000000000000838

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

KEY POINTS

- Tissue factor pathway inhibitor (TFPI) exists in two major alternatively spliced isoforms, TFPI α and TFPI β .
- TFPI α is a soluble plasma protein that is highly reliant upon its cofactors, protein S and factor V (FV)-short.
- TFPI β is a glycosylphosphatidylinositol-linked/cell surface protein that has no reliance upon cofactors.
- TFPI β function is restricted to the surface of the cell in which it is expressed.
- TFPI α (in conjunction with its cofactors, protein S and FV-short) is likely the primary regulator of the initiation of coagulation during normal haemostasis.

coagulation. Locally generated thrombin can then proteolytically convert fibrinogen into fibrin, which polymerizes to stabilize the haemostatic plug [1].

Antithrombin, protein C and tissue factor pathway inhibitor (TFPI) are the three primary anticoagulant pathways that regulate coagulation. Antithrombin is a serpin that specifically inhibits some of the free coagulation proteases – primarily FXa and thrombin, which has led to the contention that antithrombin serves to act as a buffer that controls the active half-life of these serine proteases, as well as inhibiting the activity of these proteases if they escape the site of vessel damage [2]. Activated protein C (APC) in conjunction with its cofactor, protein S, proteolytically inactivates FVa and FVIIIa, which function in the propagation phase of coagulation, dampening further thrombin generation [3]. Given that APC is generated on the endothelial surface by thrombin-thrombomodulin (i.e. adjacent to the site of vessel damage), the suggestion is that APC may also serve to limit the spread of the haemostatic response beyond the site of injury. TFPI is a Kunitz-type protease inhibitor that specifically inhibits FXa and the TF-FVIIa complex meaning that it primarily influences the initiation of coagulation [4]. These three anticoagulant pathways therefore perform distinct, nonredundant roles that control coagulation at different times and in different locations.

In humans, TFPI exists in two major alternatively spliced isoforms, TFPI α and TFPI β (Fig. 1a and b). TFPI α is composed of three tandem Kunitz domains (K1, K2 and K3) and a highly basic C-terminal tail [5]. K1 inhibits FVIIa in complex with TF, K2 specifically inhibits FXa, K3 is essential for interaction with its cofactor, protein S [6–8], and the basic C-terminal tail is involved with a high affinity interaction with FV-short [9]. TFPI β is derived from the same nascent *TFPI* transcript as TFPI α , but alternative splicing gives rise

to a TFPI molecule consisting of K1 and K2 that is directly attached to the surface of cells via a glycosylphosphatidylinositol (GPI) anchor [10]. The K1 and K2 domains of TFPI β function in the same manner as those in TFPI α , but due to the lack of K3 and the basic C-terminus, TFPI β functions independently of cofactors.

The anticoagulant function of both TFPI α and TFPI β involves a shared two-step inhibitory mechanism (Fig. 1a and b) [11]. Initially, the K2 domain of TFPI binds to and inhibits FXa. This occurs through a rate-limiting formation of an encounter complex, followed by structural isomerization that stabilizes the inhibitory complex. The second step involves the inhibition of TF-FVIIa. TFPI alone does not inhibit TF-FVIIa. Instead, inhibition of TF-FVIIa absolutely requires prior formation of the TFPI-FXa complex. Once formed, TFPI-FXa can bind to and inhibit TF-FVIIa via the K1 domain of TFPI. This dual inhibition is essential for controlling the initiation phase of coagulation. Inhibition of FXa alone (i.e. without TF-FVIIa inhibition) is ineffective in controlling coagulation, due to the ability of TF-FVIIa to continue to generate further FXa that can rapidly overwhelm TFPI inhibitory capacity. As the primary inhibitor of TF-FVIIa, TFPI plays an essential role in not only controlling TF-dependent coagulation (i.e. ensuring a small injury does not promote an excessive coagulation response), but ultimately is also responsible for shutting down persistent *de novo* initiation of coagulation. In this way, TFPI prevents excessive thrombin generation and clot formation that can be associated with thrombotic complications.

Although TFPI α and TFPI β share a common inhibitory mechanism, they differ appreciably in their dependence on cofactors as well as their abilities to inhibit coagulation in different locations. As a GPI-linked/cell surface protein, TFPI β has no reliance upon cofactors but its function is restricted to the surface of the cell in which it is expressed [12]. Conversely, as a soluble plasma protein TFPI α can function on any negatively charged cell surface to which the plasma gains access. However, to do this efficiently, TFPI α is highly reliant upon its cofactors, protein S and FV-short.

Protein S, a vitamin K-dependent plasma glycoprotein, functions as a critical cofactor for TFPI α , as well as for APC. The ability of protein S to function as a cofactor in these two distinct anticoagulant pathways appears to involve some common themes. The high affinity of protein S for negatively charged phospholipid surfaces conferred by its Gla domain is central to its cofactor roles, suggesting that protein S enhances the efficiency of recruitment of either APC or TFPI α to the surfaces upon which coagulation




FIGURE 1. Anticoagulant function of TFPI. (a) TFPI α consists of three Kunitz domains (K1–K3) and a basic C-terminus. Following exposure of TF, the TF–FVIIa complex activates FX. TFPI α K2 inactivates FXa in a rate limiting step (1). Thereafter, TFPI–FXa inhibits TF–FVIIa to form an inactive quaternary complex. (b) The alternatively spliced TFPI β consists of two Kunitz domains (K1–K2) coupled to the cell surface via a GPI-anchor. TFPI β inhibits FXa and TF–FVIIa in a two-stage mechanism similar to TFPI α . (c) TFPI α forms a high affinity trimolecular complex with FV-short and protein S. TFPI α binds the acidic region of FV-short via its basic C-terminus. TFPI α and protein S do not normally interact in the absence of phospholipid surfaces. However, once bound to FV-short protein S binds with high affinity to TFPI α . This trimolecular complex has high affinity to phospholipid surfaces, which augments TFPI α anticoagulant function. GPI, glycosylphosphatidylinositol; TFPI, tissue factor pathway inhibitor; TF, tissue factor; FVII, factor VII.

occurs. Intriguingly, the ability of protein S to interact with either APC or TFPI α appears to be dependent on protein S first associating with phospholipid surfaces as in the absence of such surfaces protein S binds APC or TFPI α with very low affinity [6,13]. Protein S enhances TFPI α anticoagulant function in a manner that is dependent upon its laminin G-type 1 domain in the sex hormone-binding globulin (SHBG)-like region, which interacts with the K3

domain of TFPI α . Several studies have revealed that substitution/mutation of the protein S SHBG-like region or the TFPI α K3 domain diminishes protein S dependent enhancement of TFPI α [13,14¹⁵]. Protein S primarily enhances the inhibitory effects of TFPI α by augmenting the rate-limiting formation of the encounter complex with FXa on phospholipid surfaces, which indirectly causes more efficient inhibition of the TF–FVIIa complex [6].

In addition to protein S, an alternatively-spliced truncated form of FV, known as FV-short exerts important anticoagulant properties by enhancing TFPI α function. Total FV plasma levels are 20–25 nM. Current estimations suggest that approximately 1–2% of FV in plasma is FV-short (0.2–0.5 nM) arising through the alternative splicing that results in the excision of the exons encoding much of the central B domain of FV [9]. In FV, the large B domain contains an acidic and a basic region, which are postulated to interact with each other [16]. In FV-short, the basic region is missing, which leaves the acidic region available [17[•]]. This negatively charged region in FV-short along with an adjacent hydrophobic patch interacts with high affinity to the positively charged C-terminal tail of TFPI α [17[•],18[•]]. The two proteins circulate as a high affinity complex in plasma that protects TFPI α from renal filtration, enabling TFPI α to persist in circulation for much longer than it otherwise would. This has led to the contention that the levels of TFPI α in plasma may be controlled by the levels of FV-short and any TFPI α that is secreted that is unable to complex with FV-short is therefore rapidly cleared. Although protein S interacts with TFPI α with low affinity in the absence of phospholipids, when in complex with FV-short, protein S appears to bind with markedly increased affinity [17[•],18[•]]. This results in TFPI α circulating in a preformed trimolecular complex with both FV-short and protein S (Fig. 1c) [17[•],18[•],19^{••}]. The formation of this complex enhances TFPI α -mediated inhibition of FXa more efficiently than with protein S alone, with the two cofactors functioning in synergism. Similar to the enhancement by protein S alone, protein S together with FV-short significantly enhances the TFPI α –FXa encounter complex formation [14[•],19^{••}].

The precise molecular basis through which protein S and FV-short augment TFPI α function remains unclear. Originally, a working hypothesis was that the high affinity interaction of protein S for phospholipids might increase the association of TFPI α with phospholipid surfaces. This contention was based on the ~4–10-fold enhancement of TFPI inhibition of FXa by protein S in the presence of phospholipids, but no effect in their absence [6,7,20]. However, this is complicated by the fact that TFPI and protein S only interact with very low affinity ($K_D > 1 \mu\text{M}$) in the absence of phospholipids [7,8,13,15]. This finding may be consistent with protein S undergoing a conformational change upon phospholipid binding that serves to augment TFPI α binding by several orders of magnitude ($K_D \sim 20 \text{ nM}$) [13,14[•],19^{••}]. This may be further supported by the finding that protein S can also only interact with APC in the protein C pathway following

phospholipid binding. Further studies are required to probe whether such conformational changes in protein S occur and how they control its different cofactor functions.

Although protein S can interact with phospholipid surfaces and enhance recruitment of TFPI α to these surfaces, it is increasingly clear that this may not be the sole mechanism involved in protein S cofactor function. The synergistic enhancement by protein S and FV-short is also completely dependent on the presence of membrane surfaces. Interestingly, FV-short binds to phospholipid surfaces with high affinity (similar to protein S), although in the absence of protein S, FV-short only very modestly enhances TFPI α inhibition of FXa [21]. This suggests that protein S fulfils additional actions (beyond recruitment to phospholipid surfaces) that augment FXa inhibition. This is supported by a recent study, showing that whilst protein S is unable to be incorporated into a TFPI α -protein S-FV-short trimolecular complex unless directly interacting with TFPI α , that same interaction is not necessary for protein S to synergistically enhance TFPI α -mediated inhibition of FXa together with FV-short [19^{••}]. This may potentially be mediated by a protein S-dependent structural/conformational changes on TFPI and/or FXa that promote their interaction.

The molecular basis of the effect of FV-short upon TFPI α inhibition of FXa is also rather uncertain. By itself, FV-short does not appreciably augment TFPI α inhibitory function. However, in the presence of FV-short, TFPI α can be maximally enhanced by lower concentrations of protein S [19^{••}]. The true physiological contribution of this effect remains unclear given that free protein S concentrations in humans (~150 nM) would be predicted to mask this effect. However, this must not diminish the potentially highly important role of FV-short in TFPI α physiology. It may well be that the most important contribution of FV-short to TFPI α is in the control/maintenance of its plasma levels through the formation of the trimolecular complex with TFPI α and protein S, although further studies are necessary to fully define the true role of FV-short *in vivo*. This is made challenging by the appreciable differences between the human and murine TFPI systems along with the predicted absence of FV-short in mice [22].

The influence of protein S upon TFPI α anticoagulant function has been well characterized *in vitro* – primarily using FXa inhibition assays and plasma-based thrombin generation assays performed under quite specific conditions to make them maximally sensitive to the effects of TFPI α [6–8,14[•],19^{••},23^{••},24,25]. From these assays, protein S can enhance the inhibition of FXa by 4–10-fold in FXa inhibition assays. In thrombin

generation assays, plasma TFPI anticoagulant function is markedly reduced in the absence of protein S [6,23^{***}]. Moreover, in the absence of protein S, at least fivefold higher concentrations of TFPI α are required to confer the same anticoagulant function as TFPI α in the presence of protein S [13]. Together, these data are consistent with the notion that protein S cofactor function is highly important given the very low concentrations of TFPI α in plasma (0.2–0.5 nM). However, it can be difficult to extrapolate such *in vitro* data to gauge the true physiological importance of protein S to TFPI α anticoagulant function as we do not know what the physiological ‘concentration’ range of TF after injury might be, as well as the absence of flow in *in vitro* systems that ordinarily provides a continued source of all clotting factors and inhibitors that can be otherwise depleted/consumed in a closed system. We recently endeavoured to address this issue *in vivo* using a murine laser-induced thrombosis model [23^{***}]. To specifically examine TFPI α anticoagulant function in mice, we blocked all endogenous murine TFPI isoforms using an antimurine K2 inhibitory antibody, which appreciably increased fibrin deposition following laser injury. Thereafter, we titrated in human TFPI α (resistant to the antimurine K2 antibody) to restore normal clot formation. Using this approach, we then specifically blocked the ability of murine protein S to function as a cofactor for human TFPI α [23^{***}]. These data demonstrated that, *in vivo*, TFPI α anticoagulant function is highly dependent upon its cofactor, corroborating the *in vitro* data. Moreover, a very similar high dependence of TFPI α upon human protein S was also detected using a humanized *ex vivo* microfluidic model of TF-dependent coagulation [23^{***}], further supporting this contention.

CONCLUSION

To endeavour to assimilate the information above and draw conclusions, it is useful to first consider how different TFPI isoforms and different TFPI cofactors might influence haemostasis at different points. Under normal conditions TFPI α circulates at 0.2–0.5 nM in plasma, as well as within platelets. Other (truncated/lipoprotein-bound) forms of TFPI exist that circulate at higher concentrations (~2 nM) than TFPI α , but due to the absence of the K3 domain and C-terminal tail (and therefore any cofactor enhancement), this pool appears to exert rather limited anticoagulant effect. This itself highlights the importance of cofactor-dependent enhancement in TFPI α anticoagulant function. Currently, data support the contention that FV-short levels determine the circulating steady-state levels of TFPI α . This is upheld by the elevated levels of TFPI α in individuals that have *F5* gene variations that increase the efficiency of the splicing events that

generate FV-short such as those with East Texas bleeding disorder, FV-Amsterdam and FV-Atlanta [9,26,27]. These 3–10-fold elevated levels of TFPI α (linked to FV-short levels) increase bleeding risk, highlighting the anticoagulant effect of plasma TFPI α and how rather small absolute increases in TFPI α levels can cause a significant phenotypic effect. Conversely, FV deficiency is associated with decreased TFPI levels and activity [28]. Moreover, as total FV levels decrease within the normal range (likely causing a similar decrease in FV-short levels), there is perhaps a paradoxical increase risk of venous thrombosis, which may be associated with decreased levels of FV-short and the effect this has on TFPI α levels, although formal demonstration of this is still required [29]. TFPI β is constitutively present on the endothelial surface. Under normal conditions the role of TFPI β remains unclear given that the endothelium is not considered a source of TF in the setting of normal haemostasis. TFPI β on the surface of other cells (particularly extravascular cells) and perhaps more importantly the TF:TFPI β ratio may represent a means of regulating the thrombogenic potential of any given cell surface.

Following blood vessel damage, the endothelial surface is disrupted. Sub-endothelial TF-presenting cells are exposed to the blood. It seems likely that on these surfaces, the TF:TFPI β ratio is conducive to initiation of thrombin generation. Therefore, the primary control of TF function on these cells may be more closely linked to the plasma TFPI α in a manner that is highly dependent upon its cofactors, protein S and FV-short. Under these circumstances, it is difficult to conceive a major role for endothelial TFPI β beyond FXa inhibition given its sequestration to the surface of cells that do not express TF. During haemostatic plug formation, platelets are recruited and activated. This can result in the local release of further TFPI α from intraplatelet stores [30]. Again, the role of this pool in the setting of normal haemostasis remains unclear given that most platelets will only get activated following the initiation of coagulation (i.e. beyond the phase that TFPI can most effectively control). This pool may therefore serve to fully shut off the initiating TF stimulus to diminish prolonged *de novo* initiation of coagulation after the clot has formed. Potentially consistent with this is the recent finding that platelet TFPI α contributes to protection against cardiac thrombosis and fibrosis in mice [31^{*}].

Based on the above contentions, TFPI α (in conjunction with its cofactors, protein S and FV-short) is likely the primary regulator of the initiation of coagulation during normal haemostasis. Consistent with this TFPI plasma levels correlate with bleeding risk in patients with severe haemophilia [32^{*}]. TFPI β

on the surface of the exposed TF-presenting cells likely plays an auxiliary role during normal haemostasis. Under pathological conditions, this may of course be different. Under inflammatory conditions, such as those that may follow initiation of venous thrombosis, during severe infections or in patients with antiphospholipid syndrome, there may be conditions that can induce local expression of endothelial TF or recruitment of TF-presenting extracellular vesicles. Under such circumstances, endothelial TFPI β may play a more prominent role in regulating the initiation of coagulation over the intact endothelium.

Acknowledgements

None.

Financial support and sponsorship

J.T.B.C. and J.A. received research funding from a British Heart Foundation programme grant (RG/18/3/33405).

Conflicts of interest

All authors report no conflicts of interest. J.A. has received research funding from AstraZeneca for work unrelated to the themes discussed herein.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Crawley JT, Zanardelli S, Chion CK, *et al.* The central role of thrombin in hemostasis. *J Thromb Haemost* 2007; 5(Suppl 1):95–101.
2. Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. *J Thromb Haemost* 2020; 18:3142–3153.
3. Griffin JH, Fernandez JA, Gale AJ, *et al.* Activated protein C. *J Thromb Haemost* 2007; 5(Suppl 1):73–80.
4. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. *Arterioscler Thromb Vasc Biol* 2008; 28:233–242.
5. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. *Arterioscler Thromb Vasc Biol* 2016; 36:9–14.
6. Hackeng TM, Sere KM, Tans G, *et al.* Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. *Proc Natl Acad Sci USA* 2006; 103:3106–3111.
7. Ahnstrom J, Andersson HM, Hockey V, *et al.* Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. *Blood* 2012; 120:5059–5062.
8. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. *Blood* 2010; 116:1344–1351.
9. Vincent LM, Tran S, Livaja R, *et al.* Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. *J Clin Invest* 2013; 123:3777–3787.
10. Zhang J, Piro O, Lu L, *et al.* Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. *Circulation* 2003; 108:623–627.
11. Maroney SA, Ellery PE, Wood JP, *et al.* Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)alpha and TFPIbeta. *J Thromb Haemost* 2013; 11:911–918.
12. Piro O, Broze GJ Jr. Comparison of cell-surface TFPIalpha and beta. *J Thromb Haemost* 2005; 3:2677–2683.

13. Reglinska-Matveyev N, Andersson HM, Rezende SM, *et al.* TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. *Blood* 2014; 123:3979–3987.
 14. Teraz-Orosz A, Gierula M, Petri A, *et al.* Laminin G1 residues of protein S ■ mediate its TFPI cofactor function and are competitively regulated by C4BP. *Blood Adv* 2022; 6:704–715.
- Identification of the aspects of protein S that interact with TFPI K3 domain.
15. Somajo S, Ahnstrom J, Fernandez-Recio J, *et al.* Amino acid residues in the laminin G domains of protein S involved in tissue factor pathway inhibitor interaction. *Thromb Haemost* 2015; 113:976–987.
 16. Wood JP, Bunce MW, Maroney SA, *et al.* Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. *Proc Natl Acad Sci USA* 2013; 110:17838–17843.
 17. Dahlback B, Tran S. The preAR2 region (1458-1492) in factor V-Short is ■ crucial for the synergistic TFPIalpha-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPIalpha. *J Thromb Haemost* 2022; 20:58–68.
- Characterization of the FV short binding site for TFPI.
18. Dahlback B, Tran S. A hydrophobic patch (PLVIVG; 1481-1486) in the B- ■ domain of factor V-short is crucial for its synergistic TFPIalpha-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIalpha, and protein S. *J Thromb Haemost* 2022; 20:1146–1157.
- Characterization of the FV short binding site for TFPI.
19. Gierula M, Noakes VM, Salles C II, *et al.* The TFPIalpha C-terminal tail is ■ essential for TFPIalpha-FV-short-protein S complex formation and synergistic enhancement of TFPIalpha. *J Thromb Haemost* 2023; 21:3568–3580.
- This study reveals the importance of the TFPI C-terminus in FV-short binding and protein S enhancement. It also reveals that protein S augments TFPI in a manner involving mechanisms beyond simple recruitment to phospholipid surfaces.
20. Santamaria S, Reglinska-Matveyev N, Gierula M, *et al.* Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. *J Biol Chem* 2017; 292:9335–9344.
 21. Dahlback B, Guo LJ, Livaja-Koshier R, *et al.* Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIalpha) cofactors. *Res Pract Thromb Haemost* 2018; 2:114–124.
 22. Girard TJ, Grunz K, Lasky NM, *et al.* Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. *J Thromb Haemost* 2018; 16:2246–2257.
 23. Petri A, Sasikumar P, Folgado PB, *et al.* TFPIalpha anticoagulant function is ■ highly dependent on protein S in vivo. *Sci Adv* 2024; 10:eadk5836.
- The first study to demonstrate the importance of protein S-TFPI α cofactor effect in vivo in mice and also to demonstrate the essential role of protein S in TFPI α function in human blood under flow.
24. Wood JP, Ellery PE, Maroney SA, *et al.* Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. *Arterioscler Thromb Vasc Biol* 2014; 34:169–176.
 25. Ndonwi M, Broze GJ Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. *J Thromb Haemost* 2008; 6:1044–1046.
 26. Cunha ML, Bakhtiari K, Peter J, *et al.* A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. *Blood* 2015; 125:1822–1825.
 27. Zimowski KL, Petrillo T, Ho MD, *et al.* F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production. *J Thromb Haemost* 2021; 19:1653–1665.
 28. Duckers C, Simioni P, Spiezia L, *et al.* Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. *Blood* 2008; 112:3615–3623.
 29. Rietveld IM, Bos MHA, Lijfering WM, *et al.* Factor V levels and risk of venous thrombosis: the MEGA case-control study. *Res Pract Thromb Haemost* 2018; 2:320–326.
 30. Maroney SA, Haberichter SL, Friese P, *et al.* Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. *Blood* 2007; 109:1931–1937.
 31. Maroney SA, Siebert AE, Martinez ND, *et al.* Platelet tissue factor pathway ■ inhibitor-alpha dampens cardiac thrombosis and associated fibrosis in mice. *J Thromb Haemost* 2023; 21:639–651.
- Using genetically modified mice, this study links the platelet pool of TFPI to protecting against arterial thrombosis and fibrosis
32. Tardy-Poncet B, Montmartin A, Chambost H, *et al.* Relationship between ■ plasma tissue factor pathway inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B. *Haemophilia* 2024; 30:693–701.
- Details the linkage between plasma TFPI levels and bleeding risk in haemophilia patients, underscoring the haemostatic potential of plasma TFPI.